ATE250593T1 - Taxal derivate, deren herstellung und diese enthaltende pharmazeutische zusammenstellungen - Google Patents

Taxal derivate, deren herstellung und diese enthaltende pharmazeutische zusammenstellungen

Info

Publication number
ATE250593T1
ATE250593T1 AT96942433T AT96942433T ATE250593T1 AT E250593 T1 ATE250593 T1 AT E250593T1 AT 96942433 T AT96942433 T AT 96942433T AT 96942433 T AT96942433 T AT 96942433T AT E250593 T1 ATE250593 T1 AT E250593T1
Authority
AT
Austria
Prior art keywords
taxal
derivatives
preparation
pharmaceutical compositions
compositions containing
Prior art date
Application number
AT96942433T
Other languages
German (de)
English (en)
Inventor
Herve Bouchard
Alain Commercon
Original Assignee
Aventis Pharma Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharma Sa filed Critical Aventis Pharma Sa
Application granted granted Critical
Publication of ATE250593T1 publication Critical patent/ATE250593T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D305/00—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms
    • C07D305/14—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/08—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Epoxy Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
AT96942433T 1995-12-22 1996-12-19 Taxal derivate, deren herstellung und diese enthaltende pharmazeutische zusammenstellungen ATE250593T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR9515379A FR2742751B1 (fr) 1995-12-22 1995-12-22 Nouveaux taxoides, leur preparation et les compositions pharmaceutiques qui les contiennent
PCT/FR1996/002031 WO1997023473A1 (fr) 1995-12-22 1996-12-19 Nouveaux taxoides, leur preparation et les compositions pharmaceutiques qui les contiennent

Publications (1)

Publication Number Publication Date
ATE250593T1 true ATE250593T1 (de) 2003-10-15

Family

ID=9485871

Family Applications (1)

Application Number Title Priority Date Filing Date
AT96942433T ATE250593T1 (de) 1995-12-22 1996-12-19 Taxal derivate, deren herstellung und diese enthaltende pharmazeutische zusammenstellungen

Country Status (40)

Country Link
US (1) US5728849A (OSRAM)
EP (1) EP0876362B1 (OSRAM)
JP (1) JP3953106B2 (OSRAM)
KR (1) KR100500351B1 (OSRAM)
CN (1) CN1103766C (OSRAM)
AR (1) AR005197A1 (OSRAM)
AT (1) ATE250593T1 (OSRAM)
AU (1) AU712597B2 (OSRAM)
BG (1) BG63204B1 (OSRAM)
BR (1) BR9612135A (OSRAM)
CA (1) CA2238884C (OSRAM)
CO (1) CO4520184A1 (OSRAM)
CZ (1) CZ294972B6 (OSRAM)
DE (1) DE69630145T2 (OSRAM)
DK (1) DK0876362T3 (OSRAM)
DZ (1) DZ2149A1 (OSRAM)
EA (1) EA001533B1 (OSRAM)
ES (1) ES2202490T3 (OSRAM)
FR (1) FR2742751B1 (OSRAM)
HU (1) HU225032B1 (OSRAM)
IL (1) IL124994A (OSRAM)
IN (4) IN186768B (OSRAM)
MA (1) MA26412A1 (OSRAM)
MX (1) MX9804688A (OSRAM)
MY (1) MY113934A (OSRAM)
NO (1) NO317358B1 (OSRAM)
NZ (1) NZ324337A (OSRAM)
OA (1) OA10700A (OSRAM)
PE (1) PE25198A1 (OSRAM)
PL (1) PL189311B1 (OSRAM)
PT (1) PT876362E (OSRAM)
RO (1) RO116194B1 (OSRAM)
SK (1) SK282835B6 (OSRAM)
TN (1) TNSN96169A1 (OSRAM)
TR (1) TR199801179T2 (OSRAM)
TW (1) TW371659B (OSRAM)
UA (1) UA48205C2 (OSRAM)
UY (1) UY24386A1 (OSRAM)
WO (1) WO1997023473A1 (OSRAM)
ZA (1) ZA9610737B (OSRAM)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9920548D0 (en) * 1999-08-31 1999-11-03 Rhone Poulenc Rorer Sa Treatment of hepatocellular carcinoma
EP1165550A1 (en) 2000-02-02 2002-01-02 Florida State University Research Foundation, Inc. C10 carbonate substituted taxanes as antitumor agents
SK286975B6 (sk) * 2001-02-24 2009-08-06 Boehringer Ingelheim Pharma Gmbh & Co. Kg Xantínové deriváty, spôsob ich výroby, farmaceutický prostriedok s ich obsahom a ich použitie
US7407955B2 (en) 2002-08-21 2008-08-05 Boehringer Ingelheim Pharma Gmbh & Co., Kg 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
WO2004103344A1 (en) * 2003-05-20 2004-12-02 Aronex Pharmaceuticals, Inc. Combination chemotherapy comprising a liposomal platinum complex
US7501426B2 (en) 2004-02-18 2009-03-10 Boehringer Ingelheim International Gmbh 8-[3-amino-piperidin-1-yl]-xanthines, their preparation and their use as pharmaceutical compositions
DE102004054054A1 (de) 2004-11-05 2006-05-11 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verfahren zur Herstellung chiraler 8-(3-Amino-piperidin-1-yl)-xanthine
EP1669358A1 (en) * 2004-12-07 2006-06-14 Aventis Pharma S.A. Cytotoxic agents comprising new taxanes
DE102005035891A1 (de) 2005-07-30 2007-02-08 Boehringer Ingelheim Pharma Gmbh & Co. Kg 8-(3-Amino-piperidin-1-yl)-xanthine, deren Herstellung und deren Verwendung als Arzneimittel
PE20110235A1 (es) 2006-05-04 2011-04-14 Boehringer Ingelheim Int Combinaciones farmaceuticas que comprenden linagliptina y metmorfina
EP1852108A1 (en) 2006-05-04 2007-11-07 Boehringer Ingelheim Pharma GmbH & Co.KG DPP IV inhibitor formulations
NZ573360A (en) 2006-05-04 2012-08-31 Boehringer Ingelheim Int Polymorphic forms of 1-[(4-methyl-quinazolin-2-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8-(3-(R)-amino-piperidin-1-yl)-xanthine
US20080207743A1 (en) * 2007-02-28 2008-08-28 Rodger Lamb Biologically Active Taxane Analogs and Methods of Treatment
ES2733348T3 (es) * 2007-08-17 2019-11-28 Boehringer Ingelheim Int Derivados de purina para uso en el tratamiento de enfermedades relacionadas con FAP
PE20091730A1 (es) 2008-04-03 2009-12-10 Boehringer Ingelheim Int Formulaciones que comprenden un inhibidor de dpp4
PE20100156A1 (es) * 2008-06-03 2010-02-23 Boehringer Ingelheim Int Tratamiento de nafld
KR20190016601A (ko) 2008-08-06 2019-02-18 베링거 인겔하임 인터내셔날 게엠베하 메트포르민 요법이 부적합한 환자에서의 당뇨병 치료
UY32030A (es) 2008-08-06 2010-03-26 Boehringer Ingelheim Int "tratamiento para diabetes en pacientes inapropiados para terapia con metformina"
MX2011001525A (es) * 2008-08-15 2011-03-29 Boehringer Ingelheim Int Derivados de purina para su uso en el tratamiento de enfermedades relacionadas con fab.
AU2009290911A1 (en) 2008-09-10 2010-03-18 Boehringer Ingelheim International Gmbh Combination therapy for the treatment of diabetes and related conditions
US20200155558A1 (en) 2018-11-20 2020-05-21 Boehringer Ingelheim International Gmbh Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug
US8865729B2 (en) 2008-12-23 2014-10-21 Boehringer Ingelheim International Gmbh Salt forms of a xanthine compound
AR074990A1 (es) 2009-01-07 2011-03-02 Boehringer Ingelheim Int Tratamiento de diabetes en pacientes con un control glucemico inadecuado a pesar de la terapia con metformina
WO2011064352A1 (en) 2009-11-27 2011-06-03 Boehringer Ingelheim International Gmbh Treatment of genotyped diabetic patients with dpp-iv inhibitors such as linagliptin
PH12012502162A1 (en) 2010-05-05 2013-02-04 Boehringer Ingelheim Int Combination therapy
KR20230051307A (ko) 2010-06-24 2023-04-17 베링거 인겔하임 인터내셔날 게엠베하 당뇨병 요법
US9034883B2 (en) 2010-11-15 2015-05-19 Boehringer Ingelheim International Gmbh Vasoprotective and cardioprotective antidiabetic therapy
PL2731947T3 (pl) 2011-07-15 2019-07-31 Boehringer Ingelheim International Gmbh Podstawiona dimeryczna pochodna chinazoliny, sposób jej wytwarzania i jej zastosowanie w kompozycjach farmaceutycznych do leczenia cukrzycy typu I i II
US9555001B2 (en) 2012-03-07 2017-01-31 Boehringer Ingelheim International Gmbh Pharmaceutical composition and uses thereof
US20130303462A1 (en) 2012-05-14 2013-11-14 Boehringer Ingelheim International Gmbh Use of a dpp-4 inhibitor in podocytes related disorders and/or nephrotic syndrome
JP6218811B2 (ja) 2012-05-14 2017-10-25 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｓｉｒｓ及び／又は敗血症の治療に用いるｄｐｐ−４阻害薬としてのキサンチン誘導体
WO2013174767A1 (en) 2012-05-24 2013-11-28 Boehringer Ingelheim International Gmbh A xanthine derivative as dpp -4 inhibitor for use in modifying food intake and regulating food preference
US10131682B2 (en) 2012-11-24 2018-11-20 Hangzhou Dac Biotech Co., Ltd. Hydrophilic linkers and their uses for conjugation of drugs to a cell binding molecules
FR3010839B1 (fr) * 2013-09-17 2017-04-21 Schneider Electric Ind Sas Dispositif de raccordement electrique d'au moins un conducteur dans une borne appartenant a un appareil electrique
DK3122757T3 (da) 2014-02-28 2023-10-09 Hangzhou Dac Biotech Co Ltd Ladede linkere og anvendelse deraf til konjugering
JP6615109B2 (ja) 2014-02-28 2019-12-04 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｄｐｐ−４阻害薬の医学的使用
CA2991973C (en) 2015-07-12 2021-12-07 Suzhou M-Conj Biotech Co., Ltd. Bridge linkers for conjugation of a cell-binding molecule
US9839687B2 (en) 2015-07-15 2017-12-12 Suzhou M-Conj Biotech Co., Ltd. Acetylenedicarboxyl linkers and their uses in specific conjugation of a cell-binding molecule
NZ747331A (en) 2016-06-10 2025-06-27 Boehringer Ingelheim Int Gmbh Combinations of linagliptin and metformin
KR102459469B1 (ko) 2016-11-14 2022-10-26 항저우 디에이씨 바이오테크 씨오, 엘티디 결합 링커, 그러한 결합 링커를 함유하는 세포 결합 분자-약물 결합체, 링커를 갖는 그러한 결합체의 제조 및 사용
WO2022078524A2 (en) 2021-11-03 2022-04-21 Hangzhou Dac Biotech Co., Ltd. Specific conjugation of an antibody

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2017724C1 (ru) * 1990-07-12 1994-08-15 Дзе Юниверсити оф Канзас Способ получения производных таксола
US5059699A (en) * 1990-08-28 1991-10-22 Virginia Tech Intellectual Properties, Inc. Water soluble derivatives of taxol
FR2678930B1 (fr) * 1991-07-10 1995-01-13 Rhone Poulenc Rorer Sa Procede de preparation de derives de la baccatine iii et de la desacetyl-10 baccatine iii.
RU2059631C1 (ru) * 1991-11-29 1996-05-10 Дзе Юниверсити оф Канзас Производные таксола и фармацевтическая композиция, обладающая противоопухолевой активностью
EP0639186B1 (en) * 1992-04-17 1999-06-23 Abbott Laboratories Taxol derivatives
US5254580A (en) * 1993-01-19 1993-10-19 Bristol-Myers Squibb Company 7,8-cyclopropataxanes
IL107950A (en) * 1992-12-15 2001-04-30 Upjohn Co 7β, 8β - METHANO-TAXOLS, THEIR PREPARATION AND ANTINEOPLASTIC PHARMACEUTICAL COMPOSITIONS CONTAINING THEM

Also Published As

Publication number Publication date
CZ196198A3 (cs) 1998-09-16
IN188470B (OSRAM) 2002-09-28
HK1017895A1 (en) 1999-12-03
BG102569A (en) 1999-04-30
WO1997023473A1 (fr) 1997-07-03
PL189311B1 (pl) 2005-07-29
AU1180997A (en) 1997-07-17
DE69630145T2 (de) 2004-07-15
IN188469B (OSRAM) 2002-09-28
AR005197A1 (es) 1999-04-14
DE69630145D1 (de) 2003-10-30
JP3953106B2 (ja) 2007-08-08
EA001533B1 (ru) 2001-04-23
SK282835B6 (sk) 2002-12-03
RO116194B1 (ro) 2000-11-30
CZ294972B6 (cs) 2005-04-13
MY113934A (en) 2002-06-29
KR100500351B1 (ko) 2005-12-21
FR2742751B1 (fr) 1998-01-30
PE25198A1 (es) 1998-05-10
SK85398A3 (en) 1998-11-04
MA26412A1 (fr) 2004-12-20
BG63204B1 (bg) 2001-06-29
MX9804688A (es) 1998-10-31
OA10700A (fr) 2002-11-27
DZ2149A1 (fr) 2002-10-23
FR2742751A1 (fr) 1997-06-27
UA48205C2 (uk) 2002-08-15
ES2202490T3 (es) 2004-04-01
IL124994A0 (en) 1999-01-26
HUP9904046A1 (hu) 2001-04-28
NZ324337A (en) 2000-03-27
TNSN96169A1 (fr) 2005-03-15
ZA9610737B (en) 1997-06-27
BR9612135A (pt) 1999-07-13
CA2238884C (fr) 2007-02-06
NO982580D0 (no) 1998-06-05
KR19990076680A (ko) 1999-10-15
IL124994A (en) 2000-12-06
CN1205697A (zh) 1999-01-20
NO317358B1 (no) 2004-10-18
EP0876362B1 (fr) 2003-09-24
CA2238884A1 (fr) 1997-07-03
PL327405A1 (en) 1998-12-07
HU225032B1 (en) 2006-05-29
US5728849A (en) 1998-03-17
CN1103766C (zh) 2003-03-26
UY24386A1 (es) 2001-08-27
IN188680B (OSRAM) 2002-10-26
IN186768B (OSRAM) 2001-11-03
AU712597B2 (en) 1999-11-11
TR199801179T2 (xx) 1998-10-21
EA199800588A1 (ru) 1998-12-24
TW371659B (en) 1999-10-11
DK0876362T3 (da) 2004-02-02
HUP9904046A3 (en) 2001-08-28
CO4520184A1 (es) 1997-10-15
PT876362E (pt) 2004-02-27
NO982580L (no) 1998-06-05
JP2000502671A (ja) 2000-03-07
EP0876362A1 (fr) 1998-11-11

Similar Documents

Publication Publication Date Title
ATE250593T1 (de) Taxal derivate, deren herstellung und diese enthaltende pharmazeutische zusammenstellungen
ATE188471T1 (de) Taxal derivate, deren herstellung und diese enthaltende pharmazeutische zusammensetzung
DE60142890D1 (de) 3-aminoazetidinderivate enthaltende pharmazeutische zusammensetzungen, diese derivate und deren herstellung
DE69131813D1 (de) Amido-3-Pyrazol-Derivate, Verfahren zu deren Herstellung und diese enthaltende pharmazeutische Zusammenstellungen
DE69928260D1 (de) Schwefel-substituierte sulfonylaminocarbonsäure n-arylamide, ihre herstellung, ihre anwendung und diese enthaltende pharmazeutische zusammensetzungen
FI934274A7 (fi) N-sulfonyyli-2-oksi-indolijohdannaiset, niiden valmistus ja niitä sisä ltävät farmaseuttiset koostumukset
DE69618587D1 (de) Chinazoline und pharmazeutische zusammensetzungen
EE9500064A (et) Asendatud 1H-imidasoolid, nende valmistamismeetodid ja farmatseutilised kompositsioonid
DE69616323D1 (de) Aromatische verbindungen und diese enthaltende pharmazeutische zusammenstellungen
DE59712959D1 (de) Orale pharmazeutische zubereitung enthaltend ibandronat
ATE297935T1 (de) 2-(iminomethyl)aminophenyl-derivate, deren herstellung, verwendung als medikamente und diese enthaltende pharmazeutische zubereitungen
FI953898A7 (fi) Glysiiniamidijohdannaisia, menetelmiä niiden valmistamiseksi ja niitä sisältäviä lääkeaineita
DE69608680D1 (de) Taxal derivate, deren herstellung und diese enthaltende pharmazeutische zusammenstellungen
DE69618210D1 (de) Aromatische verbindungen und diese enthaltende pharmazeutische zusammenstellungen
ATE222897T1 (de) Substituierte thiazolidinedione derivate, ihre herstellung und pharmazeutische zusammensetzungen,die sie enthalten
FI952550A7 (fi) Uudet N-pyridyylikarboksamidit ja johdannaiset, menetelmät niiden valmistamiseksi ja niitä sisältävät farmaseuttiset koostumukset
EE9900112A (et) 2-tsüanoiminoimidasooli derivaadid, nende valmistamismeetod, kasutamine ja farmatseutilised kompositsioonid
DE59814412D1 (de) Imidazolidinderivate, ihre Herstellung, ihre Verwendung und sie enthaltende pharmazeutische Präparate
EE04493B1 (et) Tsüklopenteeni derivaadid, neid sisaldav farmatseutiline kompositsioon ning ühendite kasutamine ravimina inimestel esinevate motiliini retseptoriga seotud häirete raviks
ATE195940T1 (de) Taxol derivate,deren herstellung und diese enthaltende pharmazeutische zusammenstellungen
FI943645A7 (fi) Uusia bakkatiini-III ja 10-deasetyylibakkatiini-III-johdannaisia, niid en valmistus ja niitä sisältäviä farmaseuttisia koostumuksia
EE9800069A (et) Bensotiasolooni derivaadid, protsessid ja kasutatud vaheühendid nende saamiseks ning neid sisaldavad ravimkoostised
HUP9900865A3 (en) Anti-viral benzimidazole derivatives, preparation and use thereof, pharmaceutical compositions containing these compounds
ATE204266T1 (de) Taxoide, ihre herstellung und diese enthaltende pharmazeutische zusammensetzungen
DE69520870D1 (de) Esculetin Derivate, Verfahren zu deren Herstellung und pharmazeutische Zusammenstellung

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 0876362

Country of ref document: EP